A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Sayeed, Abdul
- Studies on the Synthesis of Some New 1,2,4-Triazoles Derivatives and Evaluation for their Anti-Tubercular Activity Profiles
Authors
1 Mesco College of Pharmacy, Hyderabad (T.S), IN
2 Luqman College of Pharmacy, Gulbarga (KA)- 585102, IN
Source
Research Journal of Pharmacy and Technology, Vol 11, No 1 (2018), Pagination: 153-164Abstract
The synthesis of new heterocyclic compounds has always drawn the attention of medicinal chemist over the years mainly because they possess diverse biological properties.
The literature survey on 1,2,4-triazoles revealed that they are endowed with wide variety of biological activities. During the present investigation a series of new 1,2,4-triazole derivatives N-(3-(2-(3-hydrazinyl-3-oxoalkanoyl)hydrazinyl)-5(phenoxymethyl)-4H-1,2,4-triazol-4-yl)isonicotinamide(6a-6e) were synthesized by reacting with N-(5-mercapto-3-(phenoxymethyl)-4H-1,2,4-triazol-4-yl)isonicotinamide (5) and aliphatic dicarboxylic acid hydrazides (a-e).
The structures of the newly synthesized compounds were established by FT-IR, 1H-NMR and MASS spectral analysis. All the compounds synthesised 6a to 6e were evaluated for anti-tubercular activity against Mycobacterium tuberculosis H37Rv using MABA method. The compound 6a (n=0) was found to be the most potent anti-tubercular agent. Few of the other compounds in the series also showed significant anti-tubercular properties.
Keywords
1,2,4-Triazole Derivatives, Anti-Tubercular, Mycobacterium tuberculosis.
References
- Kalluraya B, Isloor P, Frank R, Jagadeesha. Indian. J, Heterocyclic Chem.2004; 13: 245-247.
- Metzer J. Comprehensive Heterocyclic Chemistry, edited by Katritzky AR, Pergamon Press, Oxford, 1984; 5: 328-331.
- Lambardino J, Wiseman E, Josephine C, J. Med. Chem. (1973); 16: 493-495.
- Burger’s ME, Medicinal Chemistry, 116-122 (Wolff Vol. IV Part III); 889- 891.
- Upmanyu N, Kumar S, Shah K, Kharya, Murli D, Mishra P. Synthesis and antimicrobial evaluation of some novel 1,2,4-triazole derivatives. Acta poloniae pharmaceutica- drug research. 2011; 68:213-221.
- Sharma R, Nagde DP, Talesare GL. Arkivoc. 2006; 1:1.
- Espinal MA. Tuberculosis. 2003; 83:44.
- Behringer H, Fischer HJ, Berichte. 1962; 96:2546.
- Hosur MS, Talwar R. Ind. J. Pharm. Sci. 1993; 55:86.
- Ilkay K, Sevim R. Farmaco. 2004; 55(11):893.
- Passannanti A, Diana P, Barraja P, Mingoia F, Lauria A, Cirrincione G. Heterocycles.1998; 48:1229.
- Jilino M, Stevens FG. J. chem. Soc, Perkin trans1. 1998; 1677.
- Diana GD, Nitz J. J. EP. 1993; 566199.
- Holla SB, Veerendra B, Shivananda MK. Eur. J. Med. Chem. 2003; 38:759.
- Udupi RH, Kulkarni VM, Purushottamachar P, Srinivasalu NJ. Ind. Chem. Soc. 2002; 79:381.
- Manfredini S, Vicentini CB, Mnafrini M, Bianchi N, Rutigliano C, Mischiati C, Gambari R. Bio org. Med. Chem. 2000; 8:2343.
- Katrizky AR, Rees CW, Scriven EF. In comprehensive heterocyclic chemistry II. Pergeman Press, Oxford, UK. 1996; 3:70.
- Kennedy AD, Summers AJ. Hetrocyclic Chem. 1981; 18:409.
- Ivoanov AB, Levin DZ, Mortikov Es. Zh.Org. khim. 1989; 25:629.
- Holla BS, Prasanna CS, Bhat UG. Ind. J. Chem.2004; 43:864.
- Raj MP, Rao JT. Asian J. Chem. 2003; 25:492.
- Maria C. S. Lourenco, Marcus V. N deSouza, Alessandra C Pinheiro, Marcelle de L. Ferreira, Rasnisb B, Goncalves, Thais Cristina M Nogneira, Monica A Peralta.“Evaluation of anti-Tubercular activity of nicotinic and isoniazid analogues” ARKIVOC 2007 (xv), 181-191.
- European committee for antimicrobial susceptibility testing (EUCAST) of the european society of clinical microbiology and infectious dieseases (ESCMID), Clinical microbiology and infection, volume-6, no. 9 September-2000,(509-515).